It's subscriber only and a video so i don't think a link will work
Key points
- Aussie market 3-6 months
- Europe q1 2018 (offices to be set up in U.K. And Germany with distributors in other countries)
- FDA approval q2 2018 at which time they will have the cash flow to drive business
- re-emphasized the dsa agreement. Looks like they definitely will partner with Hammond care in uk as a starter and take a similar approach
- pain will be recognized as a vital sign once they are finished and the market will be as big as diabetes market ($10b) if Phil has his way
He's using the cochlear and Roche playbook. I Should've bought more!
EPT Price at posting:
5.4¢ Sentiment: Buy Disclosure: Held
